Satavaptan: Difference between revisions
CSV import |
CSV import |
||
| Line 29: | Line 29: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Satavaptan structure.svg|Satavaptan | |||
</gallery> | |||
Latest revision as of 01:29, 20 February 2025
Satavaptan is a vasopressin receptor antagonist used in the treatment of hyponatremia (low blood sodium levels) associated with cirrhosis, and heart failure. It was developed by Sanofi-Aventis.
Etymology[edit]
The term "Satavaptan" is derived from the Sanskrit word "Sata", meaning "hundred", and "vaptan", which is a derivative of the term "vasopressin antagonist". This name signifies the drug's ability to antagonize the effects of vasopressin, a hormone that regulates the body's water balance, on a hundred different levels.
Mechanism of Action[edit]
Satavaptan works by blocking the action of vasopressin, a hormone that regulates the body's water balance. This results in an increase in urine production, which helps to raise blood sodium levels.
Clinical Use[edit]
Satavaptan is used in the treatment of hyponatremia associated with conditions such as cirrhosis and heart failure. It is administered orally and is available in tablet form.
Side Effects[edit]
Common side effects of Satavaptan include dry mouth, thirst, and increased urination. In some cases, it may also cause low blood pressure (hypotension), dizziness, and kidney problems.
